We're looking for people to help shape our submission to NICE's appraisal for adjuvant ribociclib for treating HER2-negative, hormone receptor positive primary breast cancer

Hi All,

My name is Ellie, I work with the Policy, Evidence and Influencing team at Breast Cancer Now. We are looking for people to help shape our input into the National Institute for Healthcare Excellence’s (NICE) appraisal into adjuvant ribociclib for treating hormone receptor positive HER-2 negative primary breast cancer for use on the NHS in England. Adjuvant therapies are treatments given after surgery.

Ribociclib is used already for some secondary, or metastatic, breast cancer patients. NICE are assessing the effectiveness of adjuvant ribociclib for treating hormone receptor positive HER2- negative primary breast cancer.

We’re looking to hear from people who have experience of this treatment for primary breast cancer for example, you may have received the treatment through the clinical trial. By sharing your experience of the treatment you’ll help to shape our input into NICEs appraisal. Anything you share will be kept anonymous.

If you’d be happy to share your experience, please email policy@breastcancernow.org by 5pm on Monday 18th December.

Thank you!